ATTR-01 for Solid Epithelial Tumors
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Recruiting
Phase 1
Phase 2
Interventional Study
Solid Tumor, Adult
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 72 (estimated)
- Sponsor
- Accession Therapeutics Limited · Industry
Who this trial is looking for
This trial is looking for adults with specific solid tumors. Participants will receive a new treatment designed to help their immune system fight the cancer.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have a solid epithelial tumor that often shows a certain marker.
- I have received standard cancer treatments that didn't work for me.
- My tumor has not been treated with radiation.
- I have measurable cancer as defined by specific criteria.
- I am in good enough health to participate.
- I expect to live more than three months.
- I am willing to follow hygiene measures to prevent virus spread.
You may not be able to join if
- I have a severe fibrotic disease or autoimmune disease.
- I have had serious side effects from PD-1 or PD-L1 therapies before.
- I have any other serious health conditions that disqualify me.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial includ…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Consenting male and female adults (18 years of age) with select solid epithelial tumour indications known to have high frequency (75 percent) of αvβ6 integrin receptor expression as detailed in the applicable SP.
* Received and failed/intolerant of Standard of Care (SoC) thera…
Contacts